U.S. market Closed. Opens in 11 hours 35 minutes

RDHL | RedHill Biopharma Ltd. Stock Fundamentals

(Stock Exchange: NASDAQ)
Analyzing fundamentals for RDHL we got that it has weak fundamentals where Valuation is considered to be overvalued, Profitability is very wealthy, Growth is bad and Health is frighteningly weak.

Valuation (40%)

Company Industry
P/E Ratio (TTM) 0.85 24.50
PEG Ratio (TTM) 0.21 2.33
P/S Ratio (TTM) 2.45 5.42
P/B Ratio (TTM) 12.50 5.06
P/FCF Ratio (TTM) -0.74 11.26
Price to 5YR AVG Earnings Ratio -0.19 5.17
Price to 5YR AVG FCF Ratio -0.24 23.99

Profitability (75%)

Company Industry
ROA (TTM) 145.57% 3.20%
ROE (TTM) 1,863.09% 31.38%
Net Profit Margin (TTM) 945.36% -10.10%
ROIC 5YR AVG -116.70% 10.85%

Growth (47%)

4QTR AVG 3YR AVG 5YR AVG
EPS 378.14% -17.76% 23.48%
Revenue -38.35% 310.51% 162.83%
Net Income 393.08% -48.28% 8.74%
Cash Flow -30.17% -23.79% -7.73%

Health (21%)

Company Industry
Current Ratio (TTM) 0.96 2.49
Quick Ratio (TTM) 0.78 1.83
D/E Ratio (TTM) 0.66 -0.01
Interest Coverage (TTM) 19.71 12.09
Piotroski F-Score 5 6
Altman Z-Score N/A 4.74
LTL to 5YR AVG FCF -0.01 4.47
Shares Outstanding Growth 5YR AVG 86.39% 28.76%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙